The Jørgensen group has strong experience in bone biology. We have three primary areas of research: 1) The role of P2 purinergic signaling in bone involving in vitro and in vivo studies (pharmacologic and P2 receptor knockout/transgenic models); 2) Genetic studies of the role of P2 receptor SNPs in normal bone metabolism and in bone related diseases (osteoporosis, inflammatory-induced bone loss, multiple myeloma); and 3) The mechanisms for mechanotransduction in bone, where ATP-mediated P2 receptor signaling is one of the main pathways for the translation of mechanical forces on bone to biological signals of increased bone formation.
Jørgensen NR, Syberg S, Ellegaard M. (2015) P2X receptor roles in bone biology. Current Medicinal Chemistry 22:902-914.
Vangsted AJ, Klausen TW, Gimsing P, Abildgaard N, Andersen NF, Gang AO, Holmstrom M, Gregersen H, Vogel U, Schwarz P, and Jorgensen NR (2014) Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma. Eur. J. Haematol. 93(2):172-4.
Jorgensen NR, Husted LB, Skarratt KK, Stokes L, Tofteng CL, Kvist T, Jensen JE, Eiken P, Brixen K, Fuller S, Clifton-Bligh R, Gartland A, Schwarz P, Langdahl BL, and Wiley JS (2012) Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with postmenopausal bone loss and vertebral fractures. Eur.J.Hum.Genet. 20, 675-681.